Are you Dr. Cannistra?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 76 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave
Beth Israel Deaconess Medical Center
Boston, MA 02215Phone+1 617-667-4283
Summary
- Dr. Stephen Cannistra, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Beth Israel Deaconess Medical Center and is a Professor of Medicine at Beth Israel Deaconess Medical Center.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1982 - 1984
Johns Hopkins UniversityResidency, Internal Medicine, 1979 - 1981
The Warren Alpert Medical School of Brown UniversityClass of 1979
Certifications & Licensure
MA State Medical License 1982 - 2021
Clinical Trials
- Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer Start of enrollment: 1999 Jul 01
- Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors Start of enrollment: 1999 Jul 01
- Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2002 May 01
Publications & Presentations
PubMed
- 74 citationsCancer of the ovary.Stephen A Cannistra
The New England Journal of Medicine. 2004-12-09 - 364 citationsGene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.Panagiotis A. Konstantinopoulos, Dimitrios Spentzos, Beth Y. Karlan, Toshiyasu Taniguchi, Elena Fountzilas
Journal of Clinical Oncology. 2010-08-01 - 124 citationsCancer of the ovary.M J McKay, C A Bull
The New England Journal of Medicine. 1994-04-07
Press Mentions
Oncologists Debate Using Maintenance Bevacizumab in Stage IIIc Ovarian CancerOctober 28th, 2019
Grant Support
- Cp-547,632 In Subjects With CancerNational Center For Research Resources2005
- Adhesion Protein And Ovarian Cancer ImplantationNational Cancer Institute1993–1996
- Role Of IA Antigens In Regulation Of Human MyelopoiesisNational Cancer Institute1985–1986
Professional Memberships
- Member
